Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Taxol reactions.

Kursteen S Price1, Mariana C Castells

  • 1Department of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, MA 02115, USA.

Allergy and Asthma Proceedings
|July 20, 2002
PubMed
Summary
This summary is machine-generated.

Paclitaxel (Taxol) hypersensitivity reactions, often seen with Cremophor EL, can be managed with premedication and longer infusions. This approach allows patients to complete chemotherapy with this vital plant-derived cancer drug.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to "Chronic Spontaneous Urticaria: The Most Common MCAS-Like Disease".

The journal of allergy and clinical immunology. In practice·2026
Same author

Rapid drug desensitization in pediatric patients: A multicenter study.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Authors' response.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Diagnosis and Management of Patients With Mast Cell Activation Syndromes: Status 2026.

The journal of allergy and clinical immunology. In practice·2025
Same author

Evaluating paclitaxel hypersensitivity reaction rates with cetirizine premedication at a large academic cancer center.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2025
Same author

Update on desensitization to chemotherapeutics and biologicals.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2025
Same journal

Key factors in the diagnosis of sesame allergy in children.

Allergy and asthma proceedings·2026
Same journal

Immunoglobulin E-mediated pumpkin seed allergy in children: Case series and narrative review with a structured literature search.

Allergy and asthma proceedings·2026
Same journal

Predictors of delayed treatment-free remission with omalizumab in chronic spontaneous urticaria.

Allergy and asthma proceedings·2026
Same journal

The digital front door: A national analysis of U.S. allergy and immunology fellowship program web sites.

Allergy and asthma proceedings·2026
Same journal

The impact of dietary patterns on the risk of asthma in children.

Allergy and asthma proceedings·2026
Same journal

The alpha-gal syndrome: Understanding the role of tick bites, and the delays in severe anaphylaxis.

Allergy and asthma proceedings·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology
  • Immunology

Background:

  • Paclitaxel (Taxol), a taxane antineoplastic agent derived from *Taxus brevifolia*, is effective against various cancers.
  • Early clinical trials of paclitaxel were significantly hampered by frequent hypersensitivity-like reactions.

Observation:

  • Hypersensitivity reactions included respiratory distress, hypotension, and angioedema, often occurring upon first exposure.
  • The vehicle, Cremophor EL, was implicated as a direct histamine releaser, independent of immunoglobulin E.
  • Initial protocols mandated treatment discontinuation for patients experiencing these reactions.

Findings:

  • Premedication strategies and extended infusion times were developed, successfully reducing the incidence of hypersensitivity reactions.
  • Despite these advancements, the precise mechanisms of paclitaxel hypersensitivity, including potential complement and mast cell activation, remain incompletely understood.

Related Experiment Videos

  • Current clinical approaches focus on managing these reactions to enable continued paclitaxel therapy.

    • Implications:

    • Effective management of hypersensitivity reactions allows for the continued use of paclitaxel, a crucial chemotherapy agent.
    • Further research into the underlying mechanisms could lead to even safer administration protocols.
    • This review provides insights into managing paclitaxel-induced hypersensitivity, aiding oncologists in completing treatment regimens.